Devyser Diagnostics AB
STO:DVYSR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
71.6
139
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Devyser Diagnostics AB
Total Liabilities & Equity
Devyser Diagnostics AB
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Devyser Diagnostics AB
STO:DVYSR
|
Total Liabilities & Equity
kr510.1m
|
CAGR 3-Years
90%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Total Liabilities & Equity
kr2.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Total Liabilities & Equity
kr778.7m
|
CAGR 3-Years
31%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Total Liabilities & Equity
kr16.9B
|
CAGR 3-Years
40%
|
CAGR 5-Years
52%
|
CAGR 10-Years
41%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Total Liabilities & Equity
kr72.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
27%
|
|
|
BioArctic AB
STO:BIOA B
|
Total Liabilities & Equity
kr1.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Devyser Diagnostics AB
Glance View
Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.
See Also
What is Devyser Diagnostics AB's Total Liabilities & Equity?
Total Liabilities & Equity
510.1m
SEK
Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Total Liabilities & Equity amounts to 510.1m SEK.
What is Devyser Diagnostics AB's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
60%
Over the last year, the Total Liabilities & Equity growth was 2%. The average annual Total Liabilities & Equity growth rates for Devyser Diagnostics AB have been 90% over the past three years , 60% over the past five years .
You don't have any saved screeners yet
